Vitamin B6 in primary hyperoxaluria I: First prospective trial after 40 years of practice

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 468-477

  Hoyer Kuhn, Heike ^a   Kohbrok, Sina ^a   Volland, Ruth ^a   Franklin, Jeremy ^b   Hero, Barbara ^a   Beck, Bodo B ^b   Hoppe, Bernd ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; OXALIC ACID; PYRIDOXINE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; ECHOGRAPHY; FATIGUE; FEMALE; GASTROENTERITIS; GENE MUTATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CALCIFICATION; KIDNEY FUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROLITHIASIS; OXALOBACTER FORMIGENES; OXALOSIS 1; PAIN; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; UROLITHIASIS;

ADMINISTRATION, ORAL; ADOLESCENT; BIOLOGICAL MARKERS; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPEROXALURIA, PRIMARY; MALE; MUTATION; OXALIC ACID; PHENOTYPE; PROSPECTIVE STUDIES; TIME FACTORS; TRANSAMINASES; TREATMENT OUTCOME; VITAMIN B 6;

EID: 84896835829     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06820613     Document Type: Article

References (45)

1. Danpure CJ: Peroxisomal alanine:glyoxylate aminotransferase and prenatal diagnosis of primary hyperoxaluria type 1. Lancet 2: 1168, 1986.
2. Motley A, Lumb MJ, Oatey PB, Jennings PR, De Zoysa PA, Wanders RJ, Tabak HF, Danpure CJ: Mammalian alanine/glyoxylate aminotransferase 1 is imported into peroxisomes via the PTS1 translocation pathway. Increased degeneracy and context specificity of the mammalian PTS1 motif and implications for the peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria type 1. J Cell Biol 131: 95-109, 1995.
3. Purdue PE, Lumb MJ, Fox M, Griffo G, Hamon-Benais C, Povey S, Danpure CJ: Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 10: 34-42, 1991.
4. Cochat P: Primary hyperoxaluria type 1. Kidney Int 55: 2533-2547, 1999.
5. Danpure CJ: Molecular and clinical heterogeneity in primary hyperoxaluria type 1. Am J Kidney Dis 17: 366-369, 1991.
6. Cochat P, Rumsby G: Primary hyperoxaluria. N Engl J Med 369: 649-658, 2013.
7. Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker-Cohen R, Weismann I, Wanders RJ, Rumsby G, Roels F, Mandel H: Intrafamilial clinical heterogeneity: Absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel. Am J Nephrol 25: 269-275, 2005.
8. Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A: Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 8: e437-e443, 2003.
9. Leumann E, Hoppe B: The primary hyperoxalurias. J Am Soc Nephrol 12: 1986-1993, 2001.
10. Mandrile G, Robbiano A, Giachino DF, Sebastiano R, Dondi E, Fenoglio R, Stratta P, Caruso MR, Petrarulo M, Marangella M, De Marchi M: Primary hyperoxaluria: report of an Italian family with clear sex conditioned penetrance. Urol Res 36: 309-312, 2008.
11. van der Hoeven SM, vanWoerden CS, Groothoff JW: Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant 27: 3855-3862, 2012.
12. Purdue PE, Takada Y, Danpure CJ: Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 111: 2341-2351, 1990.
13. Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E, Waterham H, Rumsby G: Primary hyperoxaluria type 1: Update and additional mutation analysis of the AGXT gene. Hum Mutat 30: 910-917, 2009.
14. Danpure CJ, Cooper PJ, Wise PJ, Jennings PR: An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: Peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol 108: 1345-1352, 1989.
15. Coulter-Mackie MB, Lian Q: Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: Study of a spectrum of mutations. Mol Genet Metab 89: 349-359, 2006.
16. Fargue S, Rumsby G, Danpure CJ: Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832: 1776-1783, 2013.
17. Santana A, Salido E, Torres A, Shapiro LJ: Primary hyperoxaluria type 1 in the Canary Islands: A conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci U S A 100: 7277-7282, 2003.
18. vanWoerden CS, Groothoff JW, Wijburg FA, Annink C,Wanders RJ, Waterham HR: Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 66: 746-752, 2004.
19. Gibbs DA, Watts RW: The action of pyridoxine in primary hyperoxaluria. Clin Sci 38: 277-286, 1970.
20. Watts RW, Veall N, Purkiss P, Mansell MA, Haywood EF: The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria). Clin Sci (Lond) 69: 87-90, 1985.
21. Yendt ER, Cohanim M: Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. N Engl J Med 312: 953-957, 1985.
22. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope: Primary hyperoxaluria Type 1: Indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27: 1729-1736, 2012.
23. Jamieson NV; European PHI Transplantation Study Group: A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): The European PH1 transplant registry experience 1984-2004. Am J Nephrol 25: 282-289, 2005.
24. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF: Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70: 1642-1648, 2006.
25. Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P; European Society for Pediatric Nephrology/European Renal Association- European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry: Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7: 458-465, 2012.
26. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators: Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10: 2493-2501, 2010.
27. Fargue S, Harambat J, Gagnadoux MF, Tsimaratos M, Janssen F, Llanas B, Berthélémé JP, Boudailliez B, Champion G, Guyot C, Macher MA, Nivet H, Ranchin B, Salomon R, Taque S, Rolland MO, Cochat P: Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 76: 767-773, 2009.
28. Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH: Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. NEngl J Med 331: 1553-1558, 1994.
29. Monico CG, Rossetti S, Olson JB, Milliner DS: Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67: 1704-1709, 2005.
30. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772, 2007.
31. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976.
32. Hoppe B, Kemper MJ, Hvizd MG, Sailer DE, Langman CB: Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography. Kidney Int 53: 1348-1352, 1998.
33. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H: Oxalobacter formigenes: A potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 70: 1305-1311, 2006.
34. Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D: Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26: 3609-3615, 2011.
35. Sikora P, von Unruh GE, Beck B, Feldkötter M, Zajaczkowska M, Hesse A, Hoppe B: [13C2]oxalate absorption in children with idiopathic calciumoxalate urolithiasis or primary hyperoxaluria. Kidney Int 73: 1181-1186, 2008.
36. Hofmann V, Deeg K-H, Hoyer PF: Ultraschalldiagnostik in Pä-diatrie und Kinderchirurgie: Lehrbuch und Atlas, Thieme, Stuttgart, Germany, 2012.
37. Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB: Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 58: 453-455, 2011.
38. Monico CG, Olson JB, Milliner DS: Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am J Nephrol 25: 183-188, 2005.
39. Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, Mourani C, Macher MA, Abramowicz D, Legendre C, Durrbach A, Tsimaratos M, Nivet H, Girardin E, Schott AM, Rolland MO, Cochat P: Genotype-phenotype correlation in primary hyperoxaluria type 1: The p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77: 443-449, 2010.
40. Hoppe B: Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1. Kidney Int 77: 383-385, 2010.
41. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA: Primary hyperoxaluria type 1 in The Netherlands: Prevalence and outcome. Nephrol Dial Transplant 18: 273-279, 2003.
42. Hoyer-Kuhn H, Beck BB, Hoppe B: Systemic evaluation of treatment with pyridoxalphosphate in patients with primary hyperoxaluria type I (PH I) - a pilot trial. J Am Soc Nöephrol 23: SAOR091, 2012.
43. Milliner DS, Wilson DM, Smith LH: Phenotypic expression of primary hyperoxaluria: Comparative features of types I and II. Kidney Int 59: 31-36, 2001.
44. Zarembski PM, Hodgkinson A: Some factors influencing the urinary excretion of oxalic acid in man. Clin Chim Acta 25: 1-10, 1969.
45. Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB: Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56: 268-274, 1999